Alzamend Neuro (ALZN) Preferred Stock Liabilities (2024)
Alzamend Neuro's (ALZN) quarterly Preferred Stock Liabilities came in at $477737.0 in Q1 2024.
Powered by 
Analysis
Alzamend Neuro (ALZN) Preferred Stock Liabilities (2024) Analysis & Trends
Alzamend Neuro has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $477737.0 for Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.76 Bn | 176.58 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.14 Bn | 123.29 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.69 Bn | 73.69 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.39 Bn | 55.20 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.85 Bn | 48.72 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.14 Bn | 29.84 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.79 Bn | 30.50 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | - |
| 10 | Alzamend Neuro | 5.67 Mn | 5.67 Mn | - | - |